Brief: Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
07/11/2025 14:06
Nov 7 (Reuters) - Nurix Therapeutics Inc NRIX.O: NURIX THERAPEUTICS PRESENTS NEW TRANSLATIONAL DATA FROM FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL CBL-B INHIBITOR NX-1607 DEMONSTRATING IMMUNE ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING Source text: ID:nGNX8sVwyx Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis